News Epsilogen buys rival cancer antibody firm TigaTx Epsilogen has bought TigaTx, pooling their resources to create what it says will be a leader in 'pan-isotope' cancer antibodies.
News Roche taps Oxford BioTherapeutics for cancer drug discovery Oxford BioTherapeutics has lined up another big pharma partner for its drug discovery platform, signing a $1bn deal with oncology giant Roche.
News J&J abandons work with Genmab on Darzalex successor Genmab is facing increased pressure to deliver on its in-house pipeline after Johnson & Johnson exited a partnership on a Darzalex follow-up.
News AMD shadows NVIDIA with a move into AI drug discovery Chipmaker AMD has taken a 20% stake in Absci, a specialist in the use of artificial intelligence in for biologic drug discovery.
News Genmab expands its pipeline with $630m Scancell deal Genmab has licensed another anti-glycan antibody for cancer from UK biotech Scancell as it continues to expand its in-house pipeline.
News Boehringer puts IBM's GenAI into its antibody discovery tank In another example of the pharma industry embracing generative artificial intelligence (GenAI), Boehringer Ingelheim will use technology developed by IBM to rev up antibod
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
